Prognostic significance of serum osteopontin levels in small-cell lung cancer
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Figure 1
Figure 2
Figure 3
In this work, the OPN levels were analyzed using ELISA in 96 SCLC patients before and after first-line chemotherapy and 60 healthy controls. The pre-treatment levels of serum OPN in SCLC patients were higher than those of healthy controls. Pre-treatment levels of serum OPN were significantly associated with disease stage, tumor size and lymph node metastasis. After treatment with the first-line chemotherapy, the post-treatment levels of serum OPN were obviously decreased, and correlated with treatment responses, although there was no significant difference in their pretreatment OPN levels. Cox proportional hazard analysis demonstrated that the post-treatment levels of serum OPN, disease stage and PS status were all independent predictors for overall survival of patients. The results from the current study indicate that serum level of OPN could be further confirmed as a biomarker to predict treatment responses and survival of SCLC patients.
Posted 13 Jan, 2020
On 01 Sep, 2020
On 01 Sep, 2020
On 04 Jun, 2020
Received 17 Feb, 2020
Received 17 Feb, 2020
On 07 Feb, 2020
Invitations sent on 03 Feb, 2020
On 03 Feb, 2020
On 27 Jan, 2020
On 10 Jan, 2020
On 10 Jan, 2020
On 26 Dec, 2019
Prognostic significance of serum osteopontin levels in small-cell lung cancer
Posted 13 Jan, 2020
On 01 Sep, 2020
On 01 Sep, 2020
On 04 Jun, 2020
Received 17 Feb, 2020
Received 17 Feb, 2020
On 07 Feb, 2020
Invitations sent on 03 Feb, 2020
On 03 Feb, 2020
On 27 Jan, 2020
On 10 Jan, 2020
On 10 Jan, 2020
On 26 Dec, 2019
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Figure 1
Figure 2
Figure 3
In this work, the OPN levels were analyzed using ELISA in 96 SCLC patients before and after first-line chemotherapy and 60 healthy controls. The pre-treatment levels of serum OPN in SCLC patients were higher than those of healthy controls. Pre-treatment levels of serum OPN were significantly associated with disease stage, tumor size and lymph node metastasis. After treatment with the first-line chemotherapy, the post-treatment levels of serum OPN were obviously decreased, and correlated with treatment responses, although there was no significant difference in their pretreatment OPN levels. Cox proportional hazard analysis demonstrated that the post-treatment levels of serum OPN, disease stage and PS status were all independent predictors for overall survival of patients. The results from the current study indicate that serum level of OPN could be further confirmed as a biomarker to predict treatment responses and survival of SCLC patients.